Overall rank 226 · Score 97 · 2016 Nov 10
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine
Randomized trialAI-recommended Tier AType 2 diabetesCardiovascularKidneyOphthalmicDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 227 · Score 97 · 2018 Sep
Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes, obesity & metabolism
Meta-analysisAI-recommended Tier AType 2 diabetesSafetyOphthalmic
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 228 · Score 97 · 2024 Apr
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
Expert opinion on pharmacotherapy
Systematic reviewAI-recommended Tier BWeight loss & obesityReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 229 · Score 97 · 2024 Jul 16
Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
JAMA
Systematic reviewAI-recommended Tier BDiscontinuation & regainPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 230 · Score 97 · 2016 Feb
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Diabetes care
Randomized trialAI-recommended Tier AType 2 diabetesDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 231 · Score 97 · 2024 Apr 15
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
International journal of molecular sciences
Systematic reviewAI-recommended Tier BSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 232 · Score 97 · 2024 Sep
Intentional weight loss in overweight and obese patients with heart failure: A systematic review.
European journal of heart failure
Systematic reviewAI-recommended Tier BHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 233 · Score 97 · 2024
Clinical Pharmacokinetics of Semaglutide: A Systematic Review.
Drug design, development and therapy
Systematic reviewAI-recommended Tier BKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 234 · Score 97 · 2024 Dec
The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.
European journal of clinical pharmacology
Systematic reviewAI-recommended Tier BPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 235 · Score 97 · 2018 Feb
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
The lancet. Diabetes & endocrinology
Meta-analysisAI-recommended Tier AHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 236 · Score 96 · 2023 Feb
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.
Expert review of clinical pharmacology
Systematic reviewAI-recommended Tier BReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 237 · Score 94 · 2025 Oct 30
Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Clinical trialAI-recommended Tier BType 2 diabetesCardiovascularKidneyPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 238 · Score 94 · 2025 Dec
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.
Journal of medical economics
Clinical trialAI-recommended Tier BCardiovascularKidneyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 239 · Score 94 · 2025 Mar
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.
Expert opinion on investigational drugs
Narrative reviewAI-recommended Tier DWeight loss & obesityMASH & liverSafety
AI appraisal complete: Narrative pipeline review; corrected from clinical trial. Evidence-class and Tier D recommendation updated from PubMed title/abstract, publication types, and registry metadata. No experimental retesting was performed or required.
Overall rank 240 · Score 94 · 2025 Jul 3
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
The New England journal of medicine
Clinical trialAI-recommended Tier BWeight loss & obesitySafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 241 · Score 94 · 2025 Feb 24
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Clinical trialAI-recommended Tier BMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 242 · Score 94 · 2025 Jan 11
Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.
European heart journal. Cardiovascular pharmacotherapy
Clinical trialAI-recommended Tier BType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 243 · Score 94 · 2021 Sep
Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Pharmacological research
Systematic reviewAI-recommended Tier BPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains systematic evidence synthesis with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 244 · Score 93 · 2024 Dec
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.
Alimentary pharmacology & therapeutics
Clinical trialAI-recommended Tier BMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 245 · Score 93 · 2024 Dec
Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Gastroenterology & hepatology
Commentary/editorialHeld · focused human exceptionMASH & liver
AI appraisal complete; held from the publication bundle. Two-page ESSENCE summary, not the primary phase 3 trial report; source clarification is required.
Overall rank 246 · Score 92 · 2023 Jan
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Obesity (Silver Spring, Md.)
Clinical trialAI-recommended Tier BType 2 diabetesCardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 247 · Score 92 · 2023 Aug 31
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Clinical trialAI-recommended Tier BCardiovascularKidneyHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 248 · Score 92 · 2023 Aug
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
JACC. Heart failure
Clinical trialAI-recommended Tier BCardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 249 · Score 91 · 2022 Jul
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Diabetes, obesity & metabolism
Clinical trialAI-recommended Tier BType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 250 · Score 90 · 2021 Sep 21
Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
Cell reports. Medicine
Clinical trialAI-recommended Tier BType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Source registry generated 2026-09-17; AI appraisal completed 2026-09-22 under WPF-SGLT-AI-APPRAISAL-1.0. Humans resolve only the three displayed exceptions and record one accountable bundle publication decision. Records can appear in multiple domains; domain totals therefore overlap.